Format

Send to

Choose Destination
Ann Oncol. 2015 Jun;26(6):1188-94. doi: 10.1093/annonc/mdv112. Epub 2015 Feb 23.

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.

Author information

1
Unit of Medical Oncology 2, Polo Oncologico, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa Unit of Medical Oncology 2, University of Pisa, Pisa.
2
Unit of Medical Oncology 1, Istituto Oncologico Veneto, IRCSS, Padova.
3
Department of Medical Oncology, University of Rome La Sapienza, Rome.
4
Division of Medicine and Medical Oncology, Azienda Istituti Ospitalieri, Cremona.
5
Azienda Ospedaliero-Universitaria Città Della Salute e Della Scienza, Turin.
6
Department of Medical Oncology, Fondazione Poliambulanza, Brescia.
7
Department of Medical Oncology, University Campus Biomedico, Rome.
8
Unit of Medical Oncology, Università Cattolica del Sacro Cuore, Rome.
9
Unit of Oncology, Sant'Elia Hospital, Caltanissetta.
10
Unit of Medical Oncology, San Gerardo Hospital, Monza.
11
Unit of Medical Oncology, Mater Salutis Hospital, Legnago.
12
Unit of Medical Oncology, Galliera Hospital, Genoa.
13
Department of Medical Oncology Sandro Pitigliani, Prato Hospital, Istituto Toscano Tumori, Prato.
14
Unit of Medical Oncology, Azienda Sanitaria Ospedaliera Santa Croce e Carle, Cuneo.
15
Clinical Trials Coordinating Center, Istituto Toscano Tumori, Firenze.
16
Unit of Medical Oncology 2, Polo Oncologico, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa Unit of Medical Oncology 2, University of Pisa, Pisa alfredo.falcone@med.unipi.it.

Abstract

BACKGROUND:

Early tumor shrinkage (ETS) and depth of response (DoR) predict overall survival (OS) in first-line trials of chemotherapy ± anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC). These associations and the predictive accuracy of response measurements for survival parameters were investigated in the phase III TRIBE trial of FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev.

PATIENTS AND METHODS:

A landmark approach was adopted to define the assessable population. The distribution of RECIST response rate, ETS and DoR was compared in the two arms. Associations between response measurements and progression-free survival (PFS), post-progression survival (PPS) and OS were tested by univariate and multivariate Cox models. Prediction performance of each factor was estimated by C-index.

RESULTS:

A significantly higher percentage of patients in the FOLFOXIRI plus bev arm achieved ETS ≥20%, when compared with the control arm (62.7% versus 51.9%, P = 0.025). Also the DoR was significantly higher in the triplet plus bev arm (43.4% versus 37.8%, P = 0.003). Both ETS and DoR were associated with PFS, PPS and OS at the univariate analyses and in the multivariate models stratified for other prognostic variables. Both ETS and DoR were able to predict survival as accurately as RECIST response.

CONCLUSION:

FOLFOXIRI plus bev improves ETS and DoR when compared with FOLFIRI plus bev. Achieving rapid and deep tumor shrinkage consistently delays tumor progression and prolongs survival in patients treated with first-line chemotherapy plus bev. ETS is a promising and valuable end point for clinical trials' design deserving further investigation.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00719797.

KEYWORDS:

FOLFOXIRI; bevacizumab; depth of response; early tumor shrinkage

PMID:
25712456
DOI:
10.1093/annonc/mdv112
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center